Analyzing Oncolytics Biotech (NASDAQ:ONCY) and Innate Pharma (NASDAQ:IPHA)

Oncolytics Biotech (NASDAQ:ONCY) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Risk & Volatility

Oncolytics Biotech has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

Profitability

This table compares Oncolytics Biotech and Innate Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Innate Pharma	N/A	N/A	N/A

Insider and Institutional Ownership

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Oncolytics Biotech and Innate Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1	0	2	1	2.75
Innate Pharma	1	1	1	1	2.50

Oncolytics Biotech currently has a consensus price target of $8.50, suggesting a potential upside of 1,028.82%. Innate Pharma has a consensus price target of $5.00, suggesting a potential upside of 186.53%. Given Oncolytics Biotech’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Innate Pharma.

Valuation and Earnings

This table compares Oncolytics Biotech and Innate Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76 million	($0.31)	-2.43
Innate Pharma	$10.19 million	16.08	-$55.64 million	N/A	N/A

Oncolytics Biotech has higher earnings, but lower revenue than Innate Pharma.

Summary

Oncolytics Biotech beats Innate Pharma on 6 of the 10 factors compared between the two stocks.

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.